Delving into the Latest Updates on CHO-H01 with Synapse

This is a 2-part study. Part 1/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma. It will also determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D).
Part 2/Phase 2a will assess the anticancer activity and safety of CHO-H01 plus lenalidomide in subjects with low-grade relapsed/refractory CD20+ non-Hodgkin's lymphoma.

Start Date15 Jan 2020

Sponsor / Collaborator

CHO Pharma, Inc.

NCT03221348 / Unknown statusPhase 1

A Phase I Open-label, Multiple Dose Study of CHO-H01 Administered Intravenously as a Single Agent to Subjects With Refractory or Relapsed Follicular Lymphoma

This is a single-arm open label trial to explore the tolerability, safety, PK, PD, and anti-tumor activity of various doses and schedules of CHO-H01 administered as monotherapy in subjects with follicular lymphoma.
Groups of 6 subjects are planned for each cohort. The first 3 patients of each cohort will be evaluated to determine if it is appropriate to proceed with the additional 3 patients at that dose and schedule.

Start Date01 Mar 2018

Sponsor / Collaborator

CHO Pharma, Inc.

100 Clinical Results associated with CHO-H01

Login to view more data

100 Translational Medicine associated with CHO-H01

Login to view more data

100 Patents (Medical) associated with CHO-H01

Login to view more data

100 Deals associated with CHO-H01

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Hodgkin Lymphoma	Phase 2	TW	CHO Pharma, Inc.	15 Jan 2020
Non-Hodgkin Lymphoma	Phase 2	US	CHO Pharma, Inc.	15 Jan 2020
Refractory Follicular Lymphoma	IND Application	-	CHO Pharma, Inc.	01 Mar 2018
Neoplasms	Preclinical	-	Academia Sinica	-